Epidermal growth factor receptor (EGFR) is a clinical therapeutic target to treat a subset of NSCLC harboring EGFR mutants. However, some patients with similar kind of EGFR mutation show intrinsic resistance to TKIs. It indicates that other key molecules are involved in the survival of these cancer cells. We showed here that TPCA-1, a previously reported inhibitor of IKKs, blocked STAT3 recruitment to upstream kinases by docking into SH2 domain of STAT3 and attenuated STAT3 activity induced by cytokines and cytoplasmic tyrosine kinases. TPCA-1 is an effective inhibitor of STAT3 phosphorylation, DNA-binding and transactivation in vivo. It selectively repressed proliferation of NSCLC cells with constitutive STAT3 activation. In addition, using pharmacological and genetic approaches, we found that both NFκB and STAT3 could regulate the transcripts of IL6 and COX2 in NSCLC harboring EGFR mutations.
Introduction
NFκB and STAT3 signaling pathways are found to play pivotal roles in various aspects of tumorigenic process in a number of malignancies. Most often, NFκB and STAT3 are constitutively activated in neoplastic cells (1) . However, mere disruption of either NFκB or STAT3 signaling does not lead to cell death. Previously, we have found STAT3 blockade by small chemical inhibitor often increases NFκB activity. Therefore, a dual inhibitor that is able to simultaneously block STAT3 and NFκB signaling may be a novel strategy for cancer therapy.
Lung cancer is the leading cause of cancer deaths in both men and women in the U.S and worldwide. Approximately 85-90% of all cases of lung cancer are non-small-cell lung cancer (NSCLC) (2) . Some adenocarcinoma contains constitutive EGFR activity with mutant EGFR (3, 4) . Gefitinib is the first-generation tyrosine kinase inhibitor targeting on EGFR. Nearly all gefitnib responsive lung cancers have somatic EGFR mutation with kinase domain. Exon 19 of EGFR deletion and EGFR L858R missense substitutions are found in more than 80% of non-small cell lung cancer patients that respond to gefitinib treatment (5, 6) . Although EGFR-TKI treatment therapy shows good responsive and survival rates in NSCLC patients with EGFR mutation as mentioned above (6, 7) , about 30% of NSCLC patients with activated EGFR mutations are not respond to those TKIs. In addition, TKIs responsive patients also showed different sensitivity to the treatment.
These findings indicated that other causes might also contribute to the intrinsic resistance (8) (9) (10) . Therefore, completely understanding of the causes for responsiveness to EGFR TKIs is worth pursuing to improve the clinical benefits of targeted therapies. . Increased levels of pro-inflammation cytokines such as IL6 and IL8 are also associated with non-small cell lung cancer tumorigenesis and prognosis. These indicate that IL6 and its downstream pathway are potential to be the target for patient with NSCLC harboring EGFR mutation. However, the mechanism about IL6 induction by oncogenic EGFR mutations in NSCLC is remaining unclear. IL6 had been reported to induce an autocrine IL6 loop in breast cancer (21). Therefore, we hypothesized that NFκB and STAT3 signaling were regulating IL6 autocrine in lung cancer.
Nuclear factor kappa B (NFκB) is a dimeric complex formed by RelA, RelB, and c-Rel. Activation of the NFκB is initiated by the signal-induced degradation of IκB protein (22, 23). Known inducers of NFκB activity include tumor necrosis factor alpha (TNFα), interleukin 1-beta (IL-1β) and EGF (24, 25), etc. NFκB p65 nuclear expression is an early and frequent phenomenon in the pathogenesis of lung cancers. NFκB subunit p65/RelA is determined to be required for K-Ras-induced lung tumorigenesis (26).
Furthermore, NSCLC containing EGFR mutation shows elevated NFκB activity (25). Tumor weight was measured at the endpoints of this study.
on IFNα and IFNγ. By contrast, TPCA-1 had no effect on phospho-AKT. To determine whether the STAT3 activity suppression by TPCA-1 is depend on its IKK inhibition, we examined the total IκBα and phospho-p65 levels and found no obvious changes (Fig. 1B) .
Further evidence showed that another IKK inhibitor BAY11-7082 had little influence on STAT3 phosphorylation ( Supplementary Fig. S1B ). In addition, we found that TPCA-1 also can repress STAT3 phosphorylation induced by c-src over-expression (Fig. 1C) .
Same results were observed in Hela cells ( Supplementary Fig. S1C ). SOCS3 is a major end product of STAT3 signaling and is broadly used as a marker for STAT3 activation. As shown in Fig. 1D , Socs3 transcription induced by IL6 was absolutely diminished by TPCA-1 but not BAY11-7082.
We further found that TPCA-1 severely blocked phospho-STAT3 induced by IL6 or IFNα at 500 nM or 100 nM ( Fig. 2A and Supplementary Fig. S2A ). Constitutive activated STAT3 were inhibited fiercely at 250 nM ( Supplementary Fig. S2B ). NSCLC having mutant EGFR with high STAT3 activity were treated with TPCA-1 at different time points. As seen in Fig. 2B , phospho-STAT3 was almost abrogated as early as 15 min and phosho-p65 was just slightly inhibited. These results further indicated that inhibition of TPCA-1 on constitutively activated STAT3 is more efficient than its impact on NFκB pathway. Furthermore, STAT3-dependent luciferase activity was inhibited at 100 nM ( 
TPCA-1 binds to SH2 domain of STAT3
Julio Saez-Rodriguez reported that TPCA-1 inhibits JAK2 kinase to suppress STAT3 phosphorylation induced by IL6 (30). But JAK2 is not required for IFNα and c-Src induced STAT3 activation (31). Our finding showed that TPCA-1 can inhibit STAT3 activation induced by both IFNα and c-Src. We tested whether TPCA-1 affects JAKs phosphorylation. Results showed that TPCA-1 had no effect on JAK2 induced by IFNγ (Fig. 3A) . So, we supposed there may be the other mechanism about inhibition of TPCA-1 on STAT3 pathway. Next, we want to examine whether TPCA-1 abrogates STAT3 anchoring to upstream receptors. In the cytoplasm, via the two docking autophosphorylated tyrosines (Y1068 and Y1086), cell surface EGFR physically interacts with STAT3 SH2 domain (32). STAT3 activation is partly dependent on EGFR in MDA-MB-231 cells ( Supplementary Fig. S3 ). As the Fig. 3B shown, we found that TPCA-1 blocked interaction of EGFR with STAT3 (Fig. 3B ). Based on these findings, we presumed that TPCA-1 directly target on STAT3 SH2 domain. To establish our assumption, we did molecular docking experiment subsequently. We estimated growth repressive effect of TPCA-1 on EGFR mutant NSCLC harboring constitutively activated STAT3 to other NSLCC with lower STAT3 activity.
TPCA-1 suppressed proliferation of HCC827 and H1975 cells but had little effect on A549 (Fig. 4A) . Comparing with EGFR mutant NSCLC, A549 cell has lower STAT3 activity (Fig. 4B) , which is consistent with Song's observation (37). TPCA-1 completely inhibits STAT3 phosphorylation without changing total STAT3 levels. STAT3 down-stream genes including c-myc, cyclinD and survivin were severely decreased (Fig.   4B ). Socs3 mRNA levels in HCC827 and H1975 cells were also eliminated upon TPCA-1 treatment ( Supplementary Fig. S4A ). Previous studies suggested that STAT3 activation in EGFR mutant NSCLC was driven by autocrine IL6 (19, 37). Exogenous IL6 didn't compensate the reduction of phospho-STAT3 by TPCA-1 ( Supplementary Fig. S4B ). In addition, STAT3 nucleocytoplsmic shuttling was also blocked by TPCA-1 but not BAY11 -7082 (Fig. 4C) . TPCA-1 also led to a G2/M cell cycle arrest in HCC827 but not A549
( Supplementary Fig. S5 ). We observed that STAT3 activity restoration partly rescued growth inhibition caused by TPCA-1 (Fig. 4D) . Taken together, these results suggest that TPCA-1 as a direct STAT3 inhibitor selectively suppresses NSCLC with EGFR mutant.
TPCA-1 represses IL6 autocrine and COX2 expression in EGFR mutant NSCLC.
Although STAT3 activity restoration rescued cell growth suppression in present lower dose of TPCA-1, this compensation was partial when TPCA-1 was applied in higher concentration. This might be due to the inhibition of IKKβ by TPCA-1. Over-expression of NFκB, STAT3 and IL6 might lead to the progression of lung cancer (26, 38). To determine the role of NFκB signaling in lung cancer with mutant EGFR, we knocked-down RelA in HCC827 and H1975. The growth of cells with RelA knockdown was inhibited (Fig. 5A) . We next sought to elucidate how NFκB contributed to NSCLC survival. Some pro-proliferative and anti-apoptotic downstream genes of NFκB were tested. Results showed there was no difference between scramble shRNA and RleA knockdown cells in the levels of cyclinD1 and BCL-XL except for IκBα (Fig. 5B) . Intracellular IL6 is required to control of cell proliferation in a subset of human lung cancer cells. COX2 is reported to be regulated by NFκB and is frequently expressed in Fig. S6 ). We found that mRNA levels of IL6 and COX2 were sharply repressed while RleA knocked down in HCC827 and H1975 cell (Fig. 5C) . These results showed that NFκB signaling was requisite for IL6 autocrine and COX2 expression in lung cancer.
Based on these finding, we further examined the role of NFκB pathway in mediating IL6 and COX2 expressions. Fig. 5D showed that TPCA-1 inhibited IL6 transcripts severely but not BAY11-7082. Because TPCA-1 abrogated STAT3 activity directly as above mentioned, so, we supposed IL6 autocrine and COX2 expression in EGFR mutant NSCLC are also mediated by STAT3. STAT3 dominant-negative expressing decreased about 50% of IL6 and COX2 mRNA levels. Furthermore, STAT3 over-expression increased IL6 and COX2 transcripts (Fig. 5E ). These finding suggested that NFκB was prerequisite to transcript of IL6 and COX2, and STAT3 signaling pathways was also involved in regulating IL6 autocrine and COX2 expression in HCC827 cells. Therefore, TPCA-1 as a novel inhibitor of STAT3 can block IL6 autocrine and COX2 transcription in EGFR mutant NSCLC cells.
Rationale of combined STAT3, NFκB and EGFR inhibition in EGFR mutant lung cancer
Effects of TKI on STAT3 and NFκB are not fully understood. We next investigated whether gefitinib represses activation of STAT3 and p65. Gefitinib inhibited AKT activity and STAT3 serie727 phosphorylation but no effect on STAT3 tyrosine phosphorylation (Fig. 6A) . Surprisingly, although there is lower STAT3 activity in PC9 cell line, TKI treatment obviously increased phospho-STAT3, and TPCA-1 blocked this rise.
Combination of TKI with TPCA-1 abrogated both phospho-STAT3 Y705 and S727 phosphorylation (Fig. 6A) . Although gfitinib and TPCA-1 both slightly reduced the levels of phospho-p65 in HCC827 cells, gfitinib had no impact on the level of phospho-IκBα S32. However, TPCA-1 could diminish IκBα S32 phosphorylation. Furthermore, we then discovered that co-treatment with two antagonists inhibited p65 activation potently ( We subsequently tested whether gefitinib affect mRNA levels of IL6 and COX2.
Twenty four hours after gefitnib treatment, IL6 mRNA level was significantly elevated by 5.4-fold compared to control (DMSO) and the change of COX2 level was just slight. TKI neither diminished IL6 autocrine nor COX2 transcript in sensitive NSCLCs, but combination of TPCA-1 with gefitinib repressed their transcription potently (Fig. 6C ).
To further examined the effect of inhibition of STAT3, NFκB and EGFR pathways in lung cancer cells containing EGFR mutant. We found the combination of TPCA-1 treatment increased sensitivity to gefitinib in both TKI sensitive cells and insensitive cells (Fig. 6D and Fig. S7 ). To understand whether the combination of the drugs was additive or synergistic, a Bliss independent criterion analysis was performed in HCC827 and PC9 cells. As shown in Fig. 6D , the inhibition of drugs used in combination (E observed ) was greater than the theoretical inhibition (E bliss ). The effect of these two drugs is considered synergistic. Taken together, these findings indicated that blocking STAT3, NFκB and EGFR pathways by combination of TPCA-1 with gefitnib may be served as a new strategy to EGFR mutant lung cancer.
Dual inhibition of STAT3 and NFκB pathway enhances TKI induced apoptosis via extrinsic pathway
To examine whether inhibition of STAT3 and NFțB pathways enhanced apoptosis induced by gefitinib in lung cancer cells containing EGFR mutant, we checked the effects of gefitinib and combination of gefitinib with TPCA-1 on HCC827 cells. HCC827 cells showed a pronounced increase in the percentage of apoptotic cells when compared to control, gefitinib alone (P< 0.05), or TPCA-1 alone (P< 0.01) (Fig. 7A) . Furthermore, we found that dual inhibition of STAT3 and NFκB pathway via TPCA-1 increased the level of cleaved PARP induced by Gefitinib (Fig. 7B) . TPCA-1 enhanced apoptosis through elevating cleaved caspase 8 and then caspase 3 cleavage, but not caspase 9 (Fig. 7C) . In addition, we further discovered that NFκB and STAT3 co-operated the expression of IL6 and COX2. Down regulating STAT3 activity decreased IL6 and COX2 transcription.
TPCA-1 inhibits growth of NSCLC with EGFR mutation and potentiates anti-tumor
IL6 is reported to be one of the genes downstream of COX2 in oropharyngeal carcinoma, and COX2 activates STAT3 by inducing IL6 expression in lung cancer (44, 45). Our findings inferred there were maybe two positive feedback loops for NFκB-IL6-STAT3-IL6 axis and NFκB-COX2-IL6-STAT3-COX2 axis in EGFR mutant lung cancer cells. Additionally, we found TKI treatment failed to decrease the mRNA levels of IL6 and COX2. In contrast, TPCA-1, as a novel dual IKK2 and STAT3 inhibitor, sharply inhibited COX2 and IL6 autocrine in HCC827 cells. Overall, these findings suggest that combination of EGFR and STAT3 as well NFκB inhibition may be a more effective therapeutic strategy.
In conclusion, we showed that treatment with only TKIs could not suppress activity of 
